Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.
Authors
- W. Fraser Symmans (ORCID: https://orcid.org/0000-0002-1526-184X)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Archara Supavavej (ORCID: https://orcid.org/0000-0002-3270-5553)
- Rubi Li
- Bogdan Żurawski
- Jun Ke (ORCID: https://orcid.org/0009-0004-6918-2807)
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Atsushi Yoshida (ORCID: https://orcid.org/0000-0001-5536-132X)
- Shanu Modi (ORCID: https://orcid.org/0000-0001-6427-7373)
- Pia Herbolsheimer
- Sungbae Kim (ORCID: https://orcid.org/0009-0009-4155-4679)
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-0758-8033)
- Rona Joseph
- Shinji Ohno
- Mohammad Gufran
- Adam Konpa
- Renata Meneguetti
- Santiago Escrivá-de-Romaní (ORCID: https://orcid.org/0000-0001-7816-7589)
- Xuchen Cao (ORCID: https://orcid.org/0000-0003-3216-6673)
- Zhenzhen Liu (ORCID: https://orcid.org/0000-0002-3878-1258)
- Jiong Wu (ORCID: https://orcid.org/0000-0002-8103-0505)
- Catherine Kelly (ORCID: https://orcid.org/0009-0007-8332-8528)
- Shin-Cheh Chen
- Jean-François Boileau
Institutions
- Ulsan College (KR)
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Regional Cancer Center, Thiruvananthapuram (IN)
- Asan Medical Center (KR)
- Jewish General Hospital (CA)
- Agostino Gemelli University Polyclinic (IT)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Yale Cancer Center (US)
- Chang Gung Memorial Hospital (TW)
- Yale University (US)
- University of Ulsan (KR)
- St. Luke's International Hospital (JP)
- Sociedade Brasileira de Pediatria (BR)
- AstraZeneca (South Korea) (KR)
- Fudan University Shanghai Cancer Center (CN)
- Taoyuan Chang Gung Memorial Hospital (TW)
- Cancer Trials Ireland (IE)
- Chulabhorn Hospital (TH)
- AstraZeneca (Netherlands) (NL)
- St. Luke's Medical Center (PH)
- AstraZeneca (Brazil) (BR)
- Kagoshima University Hospital (JP)
- Breast Center (CH)
- Vall d'Hebron Hospital Universitari (ES)
- AstraZeneca (Poland) (PL)
- Henan Cancer Hospital (CN)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- University of Rzeszów (PL)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1016/j.annonc.2025.10.019
- Citations
- 21
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 21.95
Funders
- AstraZeneca
- Daiichi Sankyo Europe